Skip to main content

Moderna Value Stock - Dividend - Research Selection

Moderna, Inc

ISIN: US60770K1079, WKN: A2N9D9

Market price date: 20.01.2022
Market price: 167,52 USD


Moderna, Inc Fundamental data and company key figures of the share

Annual reports in USD
Key figures 10-03-2021
Cash flow
Net operating cash flow 2.026.970.000
Capital Expenditures -67.448.000
Free cash flow 1.959.522.048
Balance sheet
Total Equity 2.561.370.000
Liabilities & Shareholders equity 7.336.750.000
Income statement
Net income -747.064.000
Eps (diluted) -1,960
Diluted shares outstanding 381.000.000
Net sales/revenue 803.395.000

Fundamental ratios calculated on: 20-01-2022

Ratios
Key figures 20-01-2022
Cash flow
P/C 31,49
   
P/FC 32,57
Balance sheet
ROI-10,18
ROE34,91
Income statement
P/E-85,47
Div. Yield0,00%
P/B24,92
P/S79,44


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



DescriptionData
SymbolMRNA
Market Capitalization63.825.121.280,00 USD
CountryUnited States
IndicesNO INDEX
SectorsBiotechnology
Raw Data SourceUS GAAP in Millionen USD
Stock Split
Internetwww.modernatx.com


Description of the company

Moderna, Inc., a clinical stage biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, and cardiovascular diseases. As of February 15, 2019 the company had 11 programs in clinical trials and a total of 20 development candidates in six modalities comprising prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company has strategic alliances with AstraZeneca, Merck & Co., Vertex Pharmaceuticals, Biomedical Advanced Research and Development Authority, Defense Advanced Research Projects Agency, and Bill & Melinda Gates Foundation; and a research collaboration with Harvard University. Moderna, Inc. also has collaborations with Lonza Ltd. for the manufacture of mRNA-1273, a COVID-19 vaccine; and Catalent for fill-finish manufacturing of its COVID-19 vaccine candidate. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov, www.modernatx.com


NEWS


Why Novavax Stock Is Already Down 30% This Year

2022-01-21
Covid-19 vaccine developer Novavax’s stock (NASDAQ: NVAX) has declined by almost 31% thus far in 2022, considerably underperforming the S&P 500, which is down by about -4.5% over the same period. Although U.S. Covid-19 daily cases have been surging (over 800,000 over

What's Happening With BioNTech Stock?

2022-01-21
BioNTech stock (NASDAQ: BNTX), a leader in messenger RNA technology and Pfizer’s Covid-19 vaccine partner, declined by almost 31% over the last month, considerably underperforming the S&P 500 which remained roughly flat over the same period. The stock also remains dow

Alpha Omega Group, Inc. Buys First Trust US Equity Opportunities ETF, CION Invt Corp, Sells ...

2022-01-20
Investment company Alpha Omega Group, Inc. (Current Portfolio) buys First Trust US Equity Opportunities ETF, CION Invt Corp, sells Salesforce.com Inc, Adobe Inc, Microsoft Corp, Bluerock Residential Growth REIT Inc, Moderna Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Alpha Omega Group, Inc..

Coronavirus pandemic ‘won’t end magically or on its own,’ doctor says

2022-01-20
Dr. Patrice Harris, former American Medical Association President, joins Yahoo Finance Live for "The Biden Presidency: Year One" special to discuss this administration's handling of COVID-19, the scarcity of testing resources and masks, being more proactive in the ongoing pandemic, and working to end it.

COVID-19: Biden administration has been 'a little bit behind the curve' on the pandemic

2022-01-20
Yahoo News reporter Andrew Romano discusses the Biden's administration's pandemic response, Americans' frustration with COVID-19 testing, and the demand for masks.

Why BioNTech, Moderna, Novavax, and Ocugen Stocks Are Plunging This Week

2022-01-20
BioNTech (NASDAQ: BNTX) stock is taking the worst drubbing, down 19.7% as of the market close on Thursday. Moderna's (NASDAQ: MRNA) shares were sinking 17.2%. Novavax (NASDAQ: NVAX) and Ocugen (NASDAQ: OCGN) stocks were falling 18.5% and 16.2%, respectively.

Florida health official urging vaccinations puts DeSantis ‘in an awkward situation,’ doctor says

2022-01-20
Dr. Adrian Burrowes, Family Medicine Physician & CFP Physicians Group CEO, joins Yahoo Finance Live to discuss how Omicron is still surging in regions such as Florida, Governor Ron DeSantis' stance on COVID-19 vaccines, and historical references for pandemic lengths.

Moderna stock fell to ‘overly high expectations:’ Jefferies Managing Director

2022-01-20
Moderna has seen a meteoric rise in growth to become a household name as one of the leading COVID-19 vaccine manufacturers. However, the stock has slumped as of late — down around 60% from a September 2021 high of nearly $450.

Benedetti & Gucer, Inc. Buys Procter & Gamble Co, iShares Core U.S. ...

2022-01-20
Investment company Benedetti & Gucer, Inc. (Current Portfolio) buys Procter & Gamble Co, iShares Core U.S.

Netflix quietly admits streaming competition is eating into growth

2022-01-20
Netflix added a line in its quarterly shareholder letter acknowledging streaming competition is affecting its "marginal growth."